 Home > Active Ingredient News > Study of Nervous System > JNNP: How can ALS patients gain weight safely and effectively?

JNNP: How can ALS patients gain weight safely and effectively?

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

pcbs health effects

soy effects men

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Weight loss is an independent prognostic factor for survival in amyotrophic lateral sclerosis (ALS), with a 1-point decrease in body mass index (BMI) being associated with a 30% increase in mortality
.

In recent years, various studies have identified weight loss and lipid metabolism as potential therapeutic targets

Monthly ALS Functional Rating Scale Revised (ALSFRS-R score) declines were slowed in HCFS patients, and light chain (NfL) levels were significantly lower in HCFS patients

This article was published in the Journal of Neurology, Neurosurgery & Psychiatry .

This study is a prospective, randomized, parallel-group, controlled trial comparing HCS as add-on therapy to normal food intake and standard therapy (riluzole) in patients with ALS
.

Patients were divided into four groups: HCFS used in the LIPCAL-ALS study, 405 kcal and 45 g fat per day
.

Patients were divided into four groups: Patients were divided into four groups:

An ultra-high calorie, fat-rich supplement (UHCFS) that provides 810 kcal and 90 g of fat per day, equivalent to double the dose study compared to LIPCAL-ALS
.

An ultra-high calorie, carbohydrate-rich supplement (UHCCS) containing 900 kcal, 111.
4 g carbohydrate, 35.
3 g protein and 34.
9 g fat (
.

The Open Control (OC) group did not receive HCS
.

Research Process

The primary endpoint of the study was tolerability, ie the incidence of adverse events (AEs) and serious AEs (SAEs)
.

Recording of AEs and SAEs included data on symptoms, physical examination, and safety laboratory values (blood counts, electrolytes, C-reactive protein, liver and kidney parameters)

Weight change in HCFS (blue), UHCFS (purple), UHCCS (orange) and OC

Gastrointestinal side effects were most common in the UHCFS group (75.
0%), while anorexia was most common in the UHCCS group (35.
3%)
.

During the intervention period, patients in the HCFS group gained +0.

The findings suggest that HCS frequently causes mild to moderate tolerance problems in ALS patients, most notably gastrointestinal symptoms in high-fat supplements, and loss of appetite in high-carbohydrate supplements
.

All three HCS tested were suitable for weight gain

HCS frequently causes mild to moderate tolerance problems in ALS patients, most notably gastrointestinal symptoms in high-fat supplements, and loss of appetite in high-carbohydrate supplements

DorstJ ,DoenzJ ,KandlerK DorstJDorst DoenzJDoenz KandlerKKandler, et alFat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled studyJournal of Neurology, Neurosurgery & PsychiatryPublished Online First:12 January 2022.
Published Online First: doi:10.
1136/jnnp-2021-328331doi:leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.